Studies carried out on the effectiveness of ICI treatments involving the use of anti-PD-1 or anti-CTLA-4 antibodies in pancreatic cancer, both alone and in combination, have revealed unsatisfactory overall response rates of 0% and 3%, respectively (17–19). Here, PDCD1 is linked to familial pancreatic carcinoma.